Clinical · Molecular biology
Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation
Summary
This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.
Critical appraisal
Clinical. This prospective early-phase trial evaluated a small cohort (n = 11) and demonstrated that preemptive frontline platinum-etoposide plus osimertinib does not reliably prevent SCLC transformation in EGFR-mutant lung cancers with TP53/RB1 co-inactivation (5 of 11 transformed; median PFS was 11 months, and median OS was 33 months). The TP53/RB1 comutation represents a strong negative prognostic and predictive biomarker of phenotypic plasticity and therapy resistance, indicating that simple chemotherapy combinations do not overcome this lineage shift. Clinical practice translation is anticipated within 3–5 years via biomarker-driven clinical trials testing epigenetic or differentiation inhibitors.
Molecular biology. The study elucidates the molecular circuitry of lineage plasticity and drug tolerance leading to SCLC, squamous, and mesenchymal states using comprehensive genomic and single-cell RNA sequencing. Mechanistically, progressive RB pathway loss drives chromatin remodeling, leading to the upregulation of neuronal differentiation and EMT programs, which are further aggravated by osimertinib exposure. These insights support using high-resolution single-cell or liquid biopsy platforms to monitor emergent clones and pave the way for trials combining targeted inhibitors with chromatin-modulating therapies.
The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology